版本:
中国

Vertex Pharmaceuticals Inc (VRTX.O)

VRTX.O ( 纳斯达克 )

168.73USD
17 May 2019
涨跌 (%)

$-1.50 (-0.88%)
收盘
$170.23
开盘
$168.90
当日最高
$170.84
当日最低
$167.97
成交量
898,185
平均成交量
1,391,933
52 周最高
$195.81
52 周最低
$144.07

概况

Vertex Pharmaceuticals Incorporated探索、开发、制造及销售用于治疗重大疾病的药品。该公司通过医药部门运营。其专注于囊胞性纤维症治疗用药的开发及商业化,以及推动实施其他病症治疗用药的研发计划。该公司销售的药品包括ORKAMBI及KALYDECO。该等药物用于治疗囊性纤维跨膜通道调节因子基... (更多)

概况

Beta: 1.54
市值(百万): $43,215.36
已发行股本(百万): 256.12
股息: --
股息收益率 (%): --

财务指标

UPDATE 2-Vertex cystic fibrosis triple combo therapy succeeds in important trials

March 6 Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening genetic condition. 全文
03/07 01:24

Vertex's cystic fibrosis therapy meets goal of late-stage studies

March 6 Vertex Pharmaceuticals Inc said on Wednesday its triple-combination therapy showed improvement in lung function for people with cystic fibrosis (CF). 全文
03/06 21:09

UPDATE 1-Vertex Pharma boots out COO for "personal behavior" violations

Jan 23 Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing "personal behavior" that violated its code of conduct. 全文
01/24 06:13

Vertex Pharma terminates interim CFO's employment for code violations

Jan 23 Vertex Pharmaceuticals Inc said on Wednesday it had terminated the employment of its chief operating officer and interim chief financial officer, Ian Smith, citing personal behavior that violated its code of conduct. 全文
01/24 05:41

REFILE-Vertex posts positive data from cystic fibrosis triple combo trials

Nov 27 Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent. 全文
11/28 02:10

CORRECTED-INSIGHT-US benefits manager baulks after Novartis values gene therapy at $4-5 mln

* At $4-5 mln, SMA treatment would be one of industry's costliest 全文
11/24 00:11

UPDATE 1-Novartis's pricing might be tested with costly eye therapy

* Swiss drugs group forging into pricey rare-disease meds (Adds comments, context about pricing, analyst quote) 全文
11/23 21:11

竞争者

  现值 涨跌额
Johnson & Johnson (JNJ.N) $138.61 +0.40
Pfizer Inc. (PFE.N) $41.47 -0.17
Novartis AG (NOVN.S) CHF84.10 +0.26
Merck & Co., Inc. (MRK.N) $78.72 -0.41
Roche Holding Ltd. (ROG.S) CHF266.15 +1.15
Roche Holding Ltd. (RO.S) CHF266.40 +1.80
Sanofi SA (SASY.PA) €75.23 +0.19
GlaxoSmithKline plc (GSK.L) 1,555.00 +5.00
AbbVie Inc (ABBV.N) $79.46 -0.04
Bristol-Myers Squibb Co (BMY.N) $46.85 -0.27

收益 vs. 预测